Blood Test to Detect Clinically Significant Prostate Cancer
Studies a blood test looking at exosome RNA to diagnose serious prostate cancer in adults.
Plain-language title generated from the registry record
Registry title: Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Key facts
- Where
- Lanzhou, Weinan, Xi'an, Xianyang, Xining, Yan’an, and Yinchuan, ChinaSee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with a high PSA blood level who are suspected of having prostate cancer and are willing to have a prostate biopsy. It tests a blood test for clinically significant prostate cancer.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Suspected prostate cancer, not yet confirmed by biopsy
- Biomarker or test result
- Blood prostate-specific antigen (PSA) above 4 ng/dl
Main reasons for not taking part
- Prostate cancer already diagnosed by prostate biopsy
- Another cancer in the past two years
- Serious complications that could affect the trial, in the study doctor's judgment
Read by machine on 12 November 2026.
Where in China
- The First Hospital of Lanzhou UniversityLanzhou, ChinaContact: Wei Zhang, MD. (principal investigator)Taking people
- Weinan Central HospitalWeinan, ChinaContact: Weihong Zhao, MD.Taking people
- Shaanxi provincial people's hospitalXi'an, ChinaContact: Yi Sun, MD.Taking people
- Xijing 986 HospitalXi'an, ChinaContact: Wuhe Zhang, MD.Taking people
- Xijing hospitalXi'an, ChinaContact: Jianhua Jiao, MD.Taking people
- The Second Affiliated Hospital of Shaanxi University of Chinese MedicineXianyang, ChinaContact: Wei Zheng, MD.Taking people
- Qinghai university affiliated hospitalXining, ChinaContact: Guojun Chen, MD.Taking people
- Yan'an University Affiliated HospitalYan’an, ChinaContact: Jixue Gao, MD.Taking people
- General Hospital of Ningxia Medical UniversityYinchuan, ChinaContact: Zhiyong Lv, MD.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT07492927
- Record updated
- 25 March 2026
- Original description
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.Read full original descriptionShow less
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Inclusion: Blood prostate-specific antigen PSA>4ng/dl; Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging; The patient is willing to undergo prostate biopsy.
Exclusion: Previous diagnosis of prostate cancer through prostate biopsy; History of other malignant tumors in the past two years; According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment.